NURIX THERAPEUTICS INC (NRIX)
US67080M1036 - Common Stock
ChartMill assigns a Buy % Consensus number of 84% to NRIX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 25.09. This target is 77.2% above the current price.
NRIX was analyzed by 17 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about NRIX.
In the previous month the buy percentage consensus was at a similar level.
NRIX was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-11 | Needham | Reiterate | Buy -> Buy |
| 2024-04-11 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-04-11 | Baird | Maintains | Outperform -> Outperform |
| 2024-04-10 | Needham | Reiterate | Buy -> Buy |
| 2024-04-09 | Needham | Reiterate | Buy -> Buy |
| 2024-04-02 | Needham | Maintains | Buy -> Buy |
| 2024-03-11 | Needham | Reiterate | Buy -> Buy |
| 2024-02-26 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-02-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-16 | Needham | Reiterate | Buy -> Buy |
| 2024-02-16 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-02-16 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-02-02 | Needham | Reiterate | Buy -> Buy |
| 2023-11-02 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-10-13 | Needham | Reiterate | Buy -> Buy |
| 2023-10-13 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-09-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-07 | Needham | Reiterate | Buy -> Buy |
| 2023-07-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-07-17 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-04-27 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-04-21 | Needham | Reiterate | Buy |
| 2023-04-14 | Needham | Reiterate | Buy |
| 2023-04-14 | RBC Capital | Reiterate | Outperform |
| 2023-03-21 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-09 | Barclays | Initiate | Overweight |
| 2023-02-28 | Oppenheimer | Initiate | Outperform |
| 2023-02-14 | Stifel | Maintains | Buy |
| 2023-02-13 | JP Morgan | Maintains | Overweight |
| 2023-02-10 | Needham | Maintains | Buy |